Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Preliminary data from a phase II study of EV in 11 heavily-treated refractory mCRPC patients demonstrated an acceptable safety profile and promising efficacy with a 64% overall response rate: no grade 5 TRAEs were reported, 5/11 patients achieved PSA decline 50%, 3/4 patients had an objective response, 4/7 had declines in CTCs, and 2/11 had stable disease for 6 months 184
[online] NutriChem Labs
Neuroscience 129 (4), 10211029
Atefi et al., 2020
L-Ascorbic Acid : High-potency, low-pH Vitamin C
Patricia Sullivan, Prakash Sampath, Albert Telfeian, Ziya Gokaslan: Manuscript Review and Editing
US$ 25.04
US$ 24.04
US$ 21.59
US$ 20.42
US$ 24.05
US$ 29.80
US$ 28.35
US$ 21.90
